TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03726775
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infusion of durvalumab during RT and after RT during 6 months
Study: NCT00189306
Drug: Imiquimod 5% cream
Normalized name: IMIQUIMOD 5% CREAM,TOP,PKT,0.25GM
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aldara (imiquimod) 5% cream - 250 mg / packet - once daily 7 days per week for 6 weeks
Study: NCT03989362
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT01592162
Drug: Propofol (Astra-Zeneca), NaCl 0.9%
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol administered by a closed-loop system and saline
Study: NCT01592162
Drug: Propofol (B-Braun) and NaCl 0.9%
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol administered by a closed-loop system and saline
Study: NCT00584935
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15).
Study: NCT01801280
Drug: Mycophenolate sodium
Normalized name: Mycophenolate Sodium
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily dose: 720mg, 1080mg, 1440mg. Application alone or together with Pantozol®.
Study: NCT01801280
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily dose: 40mg. Application together with CellCept® or Myfortic® .
Study: NCT01801280
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily dose: 1000mg, 1500mg, 2000mg. Application alone or with Pantozol® .
Study: NCT03494972
Drug: Tetracyclin ointment
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During 3rd molar surgery
Study: NCT01481545
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
Study: NCT01230424
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg into the study knee joint every 12 weeks for a total of 8 injections.
Study: NCT01481545
Drug: Raltitrexed
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1) , an additional 2 cycles of chemotherapy will be given after radiation therapy)
Study: NCT01481545
Drug: levofolinic acid
Normalized name: Levofolinic acid
DrugBank: Levoleucovorin (DB11596)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
Study: NCT01481545
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
Study: NCT01552915
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily oral dosing in the AM of optimized dose, ranging from 30- 70 mg. 5 week dose optimization, 3 week dose maintenance
Study: NCT01552915
Drug: Methylphenidate Hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily oral dosing in the AM of optimized dose, ranging from 18-72 mg. 5 week dose optimization, 3 week dose maintenance
Study: NCT02205905
Drug: 14C PER977
Normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Open-label, single dose
Study: NCT02900417
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All the patients will receive sitagliptin 100mg daily
Study: NCT01481545
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: will be given by intravenous infusion at the dose of 5 mg/kg concurrent with chemotherapy and radiotherapy every 2 weeks for 4 cycles from -14 days to start chemo-radiotherapy (classical schedule) or 4 days before the concurrent administration of chemotherapy and radiation therapy for 2 cycles if the number of TRG1 was not reached in the first stage (statistical design) with the classical schedule (for patients with resectable organ metastases (M1), one additional administration of bevacizumab will be given after radiation therapy)
Study: NCT00844909
Drug: CNTO 136
Normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
DrugBank: Carlumab (DB12718)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02503683
Drug: ALN-AAT
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple doses of ALN-AAT by subcutaneous (sc) injection
Study: NCT01722097
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02503683
Drug: Sterile Normal Saline (0.9% NaCl)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: calculated volume to match active comparator
Study: NCT01896609
Drug: Ribavirin in Arm 1
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm 1,2,3 Ribavirin in a dose of 13 mg/kg/day orally for 48 weeks
Study: NCT00651599
Drug: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)
Normalized name: Angelica seed oil
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
Study: NCT00558896
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.
Study: NCT00558896
Drug: pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).
Study: NCT00408109
Drug: VRC-AVIDNA036-00-VP
Normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00646438
Drug: Strict Glycemic Control for one year post-op CABG
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The CDE and Study Coordinator will also meet with the patient in the hospital to show how the Lifescan One-Touch Ultra II glucometer works and review the study follow-up schedule. Patients will be sent home with the Lifescan One-Touch Ultra II glucometer and a supply of strips.~Post-Discharge Period Patients will meet alternatively with the CDE and study doctor on a specific schedule including every week for the first month, every 2 weeks in the second month, and every month thereafter till the 12th month. During these sessions the BG records will be downloaded from the Lifescan One-Touch Ultra II glucometer and reviewed to see patterns and any areas that could be improved or changed.~For all patients in the study arm, the medications that are being taken and the results of glucose monitoring charts will be reviewed weekly with endocrinologists so that any additional recommendations may be made to improve glucose control.
Study: NCT02946814
Drug: essential oils without mouthwash
Normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02946814
Drug: sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02346110
Drug: Bupivacaine-adrenaline
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg bupivacaine and 50 μg adrenalin
Study: NCT02346110
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg
Study: NCT00584402
Drug: perflutren lipid microspheres
Normalized name: perflutren lipid microspheres
DrugBank: Perflutren (DB00556)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: perflutren lipid microspheres IV in 0.1 cc doses, as needed, to enhance lesion conspicuity
Study: NCT04257604
Drug: Perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel tablets.
Study: NCT01463592
Drug: Interferon Alfa-2b AND RIBAVIRIN
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
Study: NCT03188068
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral administration
Study: NCT03495739
Drug: Dabigatran Etexilate Mesylate 150 MG Oral Capsule
Normalized name: DABIGATRAN ETEXILATE MESYLATE 150 mg ORAL CAPSULE
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran Etexilate mesylate 150mg
Study: NCT03337581
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: see arms
Study: NCT02368743
Drug: mesalazine
Normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03338803
Drug: Linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: drug
Study: NCT00637819
Drug: Leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A loading dose of LEF 100mg daily for 3 days, followed by LEF 20mg daily for the remainder of the study or matching placebo
Study: NCT00493480
Drug: carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6.25 mg of carvedilol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubled weekly up to a maximum of 25 mg carvedilol daily.
Study: NCT05566834
Drug: Minnelide
Normalized name: Minnelide
DrugBank: Minnelide (DB17309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: at the MTD dose level established for monotherapy or combination to confirm safety. With a sample of 12 patients, the probability is \> 80% that a serious adverse event with at least a 16% incidence will be detected.
Study: NCT00237705
Drug: metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00493480
Drug: propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg of propranolol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubles weekly up to a maximum of 360 mg propranolol daily
Study: NCT04080518
Drug: Dapagliflozin 10 MG [Forxiga]
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 24 Hour Urine Collection, Sodium (23Na) MRI and Magnetic Resonance (MR) spectroscopy scan, Blood collection for metabolomic and osmolyte analysis
Study: NCT03942068
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a novel oral antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGFR2)
Study: NCT01185223
Drug: Valganciclovir
Normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Valganciclovir 450mg tablet or Valganciclovir powder for oral solution 50mg/mL
Study: NCT01185223
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2x5mg/kg/d intravenous ganciclovir
Study: NCT04017832
Drug: Oral semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral semaglutide to be taken every morning in a fasting state, to be followed by sitagliptin placebo after 30 minutes. Only then participants can have their first meal of the day and their pre-study metformin tablets
Study: NCT01266837
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg p.o once daily
Study: NCT02404298
Drug: IVIg
Normalized name: hIVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01436201
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04017832
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin to be taken every morning, 30 minutes after taking the oral semaglutide placebo tablet. Then participants can have their first meal of the day and their pre-study metformin tablets
Study: NCT00005046
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06259383
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-day 1 daily dose of 400 μg/kg oral ivermectin
Study: NCT03989609
Drug: Dexmedetomidine Injection [Precedex]
Normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine infusion will be started at 0.1 µg.kg-1.hr-1 and will be adjusted by 0.1 µg.kg-1.h-1 to a maximum of 0.5 µg/kg/h,
Study: NCT03989609
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam will be started at 1 mg.h-1 (3 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (15 mL.h-1).
Study: NCT00041639
Drug: hMN14 (labetuzumab)
Normalized name: MAb hMN14
DrugBank: Labetuzumab (DB05097)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02676596
Drug: K-312 10 mg QD
Normalized name: potassium gluconate
DrugBank: Potassium gluconate (DB13620)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02676596
Drug: K-312 25 mg QD
Normalized name: potassium gluconate
DrugBank: Potassium gluconate (DB13620)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04028518
Drug: r-PA
Normalized name: 89Zr-panitumumab
DrugBank: Zirconium panitumumab Zr-89 (DB19228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time.
Study: NCT04028518
Drug: r-PA
Normalized name: 89Zr-panitumumab
DrugBank: Zirconium panitumumab Zr-89 (DB19228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time.
Study: NCT04028518
Drug: Alteplase for Injection
Normalized name: Alteplase for Injection
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Alteplase for Injection Dose:50mg; 20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h.
Study: NCT02676596
Drug: K-312 50 mg QD
Normalized name: potassium gluconate
DrugBank: Potassium gluconate (DB13620)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02676596
Drug: K-312 100 mg QD
Normalized name: potassium gluconate
DrugBank: Potassium gluconate (DB13620)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02676596
Drug: K-312 200 mg QD
Normalized name: potassium gluconate
DrugBank: Potassium gluconate (DB13620)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02676596
Drug: K-312 400 mg QD
Normalized name: potassium gluconate
DrugBank: Potassium gluconate (DB13620)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00001599
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04144036
Drug: Neihulizumab, 6 mg/kg
DrugBank: Neihulizumab (DB16698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
Study: NCT04144036
Drug: Neihulizumab, 9 mg/kg
DrugBank: Neihulizumab (DB16698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
Study: NCT04144036
Drug: Neihulizumab
Normalized name: Neihulizumab
DrugBank: Neihulizumab (DB16698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm will receive the Maximum Tolerated Dose determined in the Drug Escalation phase.
Study: NCT04450134
Drug: Fexofenadine Hydrochloride
Normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H1 receptor antagonist: 540 mg Fexofenadine Hydrochloride
Study: NCT04450134
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H2 receptor antagonist: 40 mg Famotidine
Study: NCT04127513
Drug: Ammonium Lactate
Normalized name: Ammonium Lactate
DrugBank: Ammonium lactate (DB06768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12% ammonium lactate moisturizing cream
Study: NCT04617847
Drug: WVE-120101
Normalized name: WVE 003
DrugBank: WVE-003 (DB17870)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WVE-120101 is a stereopure antisense oligonucleotide (ASO). It is administered monthly via intrathecal injection.
Study: NCT03762928
Drug: PF-06651600
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 milligram (mg) PF-06651600 once daily (QD) orally for 11 days
Study: NCT03762928
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single administration of midazolam 2 mg oral solution
Study: NCT03762928
Drug: efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single administration of efavirenz 50 mg capsule
Study: NCT00005876
Drug: rubitecan
Normalized name: Rubitecan
DrugBank: Rubitecan (DB06159)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02767492
Drug: Kenalog
Normalized name: Kenalog
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active comparator, Kenalog steroid, will be injected into the articular space of the knee.
Study: NCT02344290
Drug: Pitavastatin
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet (4 mg) taken once daily, orally with or without food
Study: NCT01433445
Drug: panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given 3 times a week, every other week in 28-day cycles.
Study: NCT01433445
Drug: ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given twice daily in 28-day cycles.
Study: NCT00865917
Drug: beta-blocker (Metoprolol)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 95 mg once per day
Study: NCT00865917
Drug: I(f)-blocker (ivabradine)
Normalized name: IOBENGUANE I 123
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 7.5 mg once per day
Study: NCT01083966
Drug: Bevacizumab (Avastin)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Super-Selective Intraarterial Intracranial Infusion of Bevacizumab in Vestibular Schwannoma~This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival and hearing function of patients with VS
Study: NCT00810446
Drug: rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily.~3.Inhibition of disseminated Mycobacterium avium complex (MAC) disease associated with HIV infections : The usual adult dosage for oral use is 300 mg of rifabutin once daily..
Study: NCT00224458
Drug: Truvada
Normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00224458
Drug: efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04450407
Drug: Insulin Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC
Study: NCT01945437
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The magnesium group receive intravenous magnesium sulfate.
Study: NCT03061656
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1st HDCT
Study: NCT03061656
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1st HDCT
Study: NCT03061656
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2nd HDCT
Study: NCT02623010
Drug: Imbruvica
Normalized name: Imbruvica
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bruton's Tyrosine Kinase Inhibitor Ibrutinib as maintenance treatment in elderly patients with primary CNS lymphoma following first line chemotherapy treatment
Study: NCT04138836
Drug: BBT-877
Normalized name: BBT-877
DrugBank: BBT-877 (DB18668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBT-877 oral capsule.